Takeda Pharmaceutical announced successful results from two Phase III studies evaluating its oral orexin receptor 2-selective agonist, oveporexton, for narcolepsy type 1. The drug met all primary and secondary endpoints, significantly improving symptoms such as excessive daytime sleepiness and muscle weakness without serious adverse events. Takeda plans to file for regulatory approval within its 2025 fiscal year. This marks the first late-stage validation of the orexin receptor 2 agonist mechanism, opening a potential multibillion-dollar market for narcolepsy therapeutics.